Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).
NCT ID: NCT02202538
Last Updated: 2017-07-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2014-08-31
2015-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Indego Exoskeleton After SCI
NCT02793635
Mobility and Therapeutic Benefits Resulting From Exoskeleton Use in a Clinical Setting (SC140121 Study 1 and 2)
NCT03082898
Seated Balance Using the Indego™
NCT04047992
Self-balancing Personal Exoskeleton for SCI (WINY)
NCT07222033
Lower-Limb Exoskeleton Technology for Non-Ambulatory Individuals With Spinal Cord Injury
NCT07128901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Indego
Indego
Indego
Indego
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Indego
Indego
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Height 5'1" to 6'3" (Acceptable height may vary by a few inches depending on femur length).
* Hip width as measured in sitting no greater than 16.6" (42 cm) (acceptable hip width may vary depending on soft tissue).
* Femur length as measured in sitting must be between 14 inches (35.5cm) and 18.5 inches (47 cm)
* Weight 250lbs (113.4 kg) or less
* Present with Spinal Cord Injury and NLI C5 and lower, with ISNCSCI A, B, C or D who are non-ambulatory or poorly ambulatory.
* There are no restrictions on time since injury. However, each subject must have signed medical clearance/approval for full weight bearing and locomotor training.
* Determined to have sufficient bone health for walking with full weight bearing without undue risk for fracture. Meeting of this criterion is at the discretion of each subject's personal MD and must be approved by each site's Medical PI.
* Passive range of motion (PROM) at shoulders, trunk, upper extremities and lower extremities within functional limits for safe gait and use of appropriate assistive device/stability aid.
* Skin must be intact where it interfaces with robotic device
* Modified Ashworth Scale for spasticity score must be 3 or less.
* Blood pressure and heart rate within established guidelines for locomotor training:
* At rest; Systolic 150 or less Diastolic 90 or less and Heart rate 105 or less
* Exercise; Systolic 180 or less Diastolic 105 or less and Heart Rate 145 or less
* Tolerate being in an upright standing position (passive or active) without being lightheaded or having a headache.
Exclusion Criteria
* Heterotopic ossification that, in the opinion of the investigator, would place the subject at undue risk for fracture.
* Any subject deemed at increased risk for injury by Medical Personnel
* Lower extremity joint limitation that exceeds 10 degrees at their hips, knees or ankles.
* Light headedness or headache in standing position (active or passive)
* Moderate to Severe Traumatic (or Acquired) Brain Injury
* Inability to follow instructions
* Colostomy bag
* Women who are pregnant or attempting to become pregnant during the study intervention.
* Unable to obtain informed consent (either from the subject or from the subjects Legally Authorized Representative).
* Any disease, concomitant injury, or condition that interferes with the performance or interpretation of the protocol specified assessments
* Unlikely to be available for follow-up phone call.
* Any other issue which, in the opinion of the investigators, will make the subject unsuitable for study participation.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parker Hannifin Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Craig Hospital
Englewood, Colorado, United States
Shepherd Center
Atlanta, Georgia, United States
Rehabilitation Institue of Chicago
Chicago, Illinois, United States
Kessler Institute for Rehabilitation
West Orange, New Jersey, United States
RUSK Rehabilitation Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PH-IND01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.